TAGRISSO (osimertinib)

TAGRISSO is an EGFR TKI indicated as a monotherapy for:

First-line TAGRISSO

FLAURA study design

FLAURA is a phase III, randomised, double-blind, international trial comparing TAGRISSO versus first-generation TKIs, gefitinib and erlotinib, in 556 patients with EGFR mutated NSCLC:2

FLAURA study design
FLAURA study design